Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
Add more filters










Publication year range
1.
Leukemia ; 16(3): 352-61, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11896538

ABSTRACT

The immortalized murine stromal cell line AFT024 has been reported to maintain human hematopoietic progenitors in an undifferentiated state in vitro. In the current studies the beige/nude/xid (bnx) mouse in vivo xenograft model was used to examine the engraftment and multilineage generative potential of human hematopoietic progenitors after 2-3 weeks growth on AFT024 stroma, in comparison to primary stromal monolayers derived from post-natal human bone marrow. Eight to 12 months after transplantation of human CD34+CD38- cells from umbilical cord blood, cultured on AFT024 vs human stroma for 2-3 weeks, the murine bone marrow was harvested and analyzed for the presence of human myeloid and lymphoid cells. The mean percent engraftment of total human hematopoietic cells in the murine marrow was significantly higher after co-cultivation on AFT024 than on human stroma. Human myeloid and lymphoid lineage cells were detected in all mice. However, engraftment of myeloid lineage cells (CD33+), B lymphoid (CD19+), and T lymphoid cells (CD4+and CD8+) were significantly higher after co-cultivation of the human cells on AFT024 than on human stroma, prior to transplantation. Interestingly, the length of time in culture did not significantly affect the engraftment of the myeloid and T lymphoid lineage progenitors, but the percentage of B lymphoid lineage engraftment decreased significantly between 2 and 3 weeks of co-cultivation on both types of stroma. Cells with a primitive phenotype (CD45+/CD34-/CD38- and CD45+/CD34-/lin-) and cells with the capacity to generate secondary human CFU after recovery from the bnx bone marrow were maintained at significantly higher levels during culture on AFT024 stroma than on human stroma. The current studies demonstrate that the AFT024 murine stromal cell line supports the ex vivo survival and maintenance of human hematopoietic progenitors that are capable of long-term multilineage reconstitution for 2-3 weeks ex vivo, to levels superior to those that can be obtained using human stromal cells.


Subject(s)
Bone Marrow Transplantation/immunology , Hematopoiesis/immunology , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/immunology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Animals , Antigens, CD/blood , Antigens, Differentiation , B-Lymphocytes/immunology , Bone Marrow/immunology , Bone Marrow Cells , Cells, Cultured , Fetal Blood/cytology , Graft Survival , Humans , Immunophenotyping , Membrane Glycoproteins , Mice , Mice, SCID , NAD+ Nucleosidase , Stromal Cells/immunology , T-Lymphocytes/immunology , Transplantation, Heterologous
3.
Clin Immunol ; 100(3): 339-48, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11513547

ABSTRACT

We have previously described extrathymic generation of human T cells from purified stem cells in the bone marrow of athymic immune deficient mice. This system provides a pure population of extrathymic human T cells that is devoid of contamination by peripheral expansion of thymic-selected T cells. In the current studies, we phenotypically compared the extrathymic human T cells (Ex-T) to T cells from human peripheral blood leukocytes (PBL), umbilical cord blood (CB), bone marrow (BM), and postnatal thymus. There were few CD4(+)/CD8(+) double positive (DP) cells in PBL, CB, BM, and Ex-T, in comparison with over 85% DP cells in thymus. More CD8(+) and CD4(dim) cells were observed in Ex-T than in the thymic-selected cells. Ex-T and T cells in thymus and peripheral tissues differed in their CD8 isoforms. There were more TCRgamma/delta T cells in PBL, CB, BM, and Ex-T than in thymus. Similar to the bright CD3(+) T cells in thymus, T cells in PBL, CB, and BM were CD3 bright and expressed the adhesion molecules CD44 and L-selectin (CD62L), while intermediate CD3 T cells in thymus lacked CD44 and L-selectin. However, the majority of Ex-T only expressed CD44 but not L-selectin. In summary, thymic- and extrathymic-derived T cells are phenotypically different. The identification of extrathymically derived T cells in humans will allow us to begin to understand their role in the early contribution to immune recovery posttransplantation and their possible involvement in autoimmunity and other disease states.


Subject(s)
Bone Marrow Cells/immunology , T-Lymphocytes/immunology , Thymus Gland/cytology , CD4 Antigens/analysis , CD8 Antigens/analysis , Humans , Hyaluronan Receptors/analysis , Immunophenotyping , Protein Isoforms , Receptors, Antigen, T-Cell, alpha-beta/analysis , Receptors, Interleukin-2/analysis
4.
J Immunol ; 166(1): 170-81, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11123290

ABSTRACT

The beige/nude/xid/human (bnx/hu) model of human hematopoiesis provides a unique opportunity to study extrathymic human T lymphocyte development in an in vivo system. Purified human hematopoietic stem cells develop into mature T lymphocytes and immature progenitors in the bone marrow of athymic bnx mice. The human T cells are all TCR alpha beta(+) and display a restricted TCRV beta repertoire. In the current studies, we examined the effects of systemic human IL-7 (huIL-7) administration on the phenotype and the activation status of the bnx/hu T cells. In the majority of the mice that did not have huIL-7 administration, a higher frequency of human CD3(+)/CD8(+) than CD3(+)/CD4(+) T cells developed in the bone marrow. This phenomenon is also frequently observed in human bone marrow transplant recipients. Extremely low levels of IL-2 were expressed by human CD3(+) cells isolated from these mice, in response to PMA plus ionomycin and to CD3 and CD28 cross-linking. IL-4 was not expressed by cells exposed to either stimulus, demonstrating a profound inability of the bnx/hu T cells to produce this cytokine. Systemic production of huIL-7 from engineered stromal cells transplanted into the mice increased the human CD4 to CD8 ratios, and increased the ratio of memory to naive CD4(+) and CD8(+) T cells. The human CD3(+) cells recovered from mice that had systemic huIL-7 and equivalent numbers of CD3(+)/CD4(+) and CD3(+)/CD8(+) cells in the marrow were still unable to produce IL-4 in response to any condition tested, but were capable of normal levels of IL-2 production following stimulation.


Subject(s)
Adjuvants, Immunologic/physiology , Bone Marrow Cells/immunology , Interleukin-7/physiology , Mice, Nude/genetics , Mice, Nude/immunology , T-Lymphocyte Subsets/immunology , Animals , Bone Marrow Cells/cytology , Bone Marrow Transplantation , CD4 Antigens/biosynthesis , CD4-Positive T-Lymphocytes/metabolism , CD8 Antigens/biosynthesis , CD8-Positive T-Lymphocytes/metabolism , Cell Differentiation/genetics , Cell Differentiation/immunology , Cell Separation , HLA-DR Antigens/biosynthesis , Humans , Interleukin-2/biosynthesis , Interleukin-2/genetics , Interleukin-4/biosynthesis , Interleukin-4/genetics , Interleukin-7/biosynthesis , Interleukin-7/metabolism , Leukocyte Common Antigens/biosynthesis , Lymphocyte Activation , Mice , Mice, Inbred C57BL , RNA, Messenger/biosynthesis , Receptors, Interleukin-2/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/metabolism , Transplantation Chimera/immunology
5.
Infect Control Hosp Epidemiol ; 21(10): 659-73, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11083185

ABSTRACT

Gene therapy is being studied for the treatment of a variety of acquired and inherited disorders. Retroviruses, adenoviruses, poxviruses, adeno-associated viruses, herpesviruses, and others are being engineered to transfer genes into humans. Treatment protocols using recombinant viruses are being introduced into clinical settings. Infection control professionals will be involved in reviewing the safety of these agents in their clinics and hospitals. To date, only a limited number of articles have been written on infection control in gene therapy, and no widely available recommendations exist from federal or private organizations to guide infection control professionals. The goals of the conference were to provide a forum where gene therapy experts could share their perspectives and experience with infection control in gene therapy and to provide an opportunity for newcomers to the field to learn about issues specific to infection control in gene therapy. Recommendations for infection control in gene therapy were proposed.


Subject(s)
Genetic Therapy , Infection Control , Virus Diseases/therapy , Congresses as Topic , Female , Genetic Therapy/adverse effects , Genetic Therapy/methods , Genetic Therapy/trends , Guidelines as Topic , Humans , Infection Control/methods , Infection Control/standards , United States , United States Food and Drug Administration
6.
Leukemia ; 14(5): 773-6, 2000 May.
Article in English | MEDLINE | ID: mdl-10803504

ABSTRACT

Recent evidence suggests that expression of CD34 on the cell membrane does not always correlate with stem cell activity. In the mouse, there is a highly quiescent population of stem cells that lacks CD34 expression, but has full reconstituting capacity. The current review addresses the discovery of a similar population of dormant CD34-negative human hematopoietic stem cells. This information casts some uncertainty on the benefits of CD34+ cell isolation for stem cell transplantation, until more is known about the novel CD34-negative stem cell population. Methods designed to achieve removal of specific mature blood cell lineages might prove to be most advantageous in the future.


Subject(s)
Antigens, CD34/analysis , Antigens, CD/analysis , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Animals , Cell Separation/methods , Humans , Mice , Transplantation, Heterologous
7.
Curr Opin Immunol ; 11(5): 532-7, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10508705

ABSTRACT

The past year has brought forth some exciting developments in the use of murine xenotransplantation systems to study the biology and transduction of human hematopoietic stem cells. The effects of cytokines have been studied by injection into the mice or by treatment of the cell inoculum prior to injection. The importance of the cell cycle and integrin expression has been evaluated. New methods of gene therapy have been tested in xenograft models - including cell cycle manipulation and a promising new lentiviral vector system, based on HIV.


Subject(s)
Hematopoietic Stem Cell Transplantation , Immune Tolerance , Mice, Mutant Strains/immunology , Transplantation Immunology , Transplantation, Heterologous/immunology , Animals , Humans , Mice , Mice, Inbred NOD/immunology , Mice, SCID/immunology , Models, Immunological
8.
J Leukoc Biol ; 65(4): 523-34, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10204582

ABSTRACT

Cbl is a cytosolic protein that is rapidly tyrosine phosphorylated in response to Fc receptor activation and binds to the adaptor proteins Grb2, CrkL, and Nck. A few reports describe Cbl interactions in primary human hematopoietic cells. We show evidence that Cbl participates in signaling initiated by Fc gammaRI receptor cross-linking in human primary macrophages, and functions downstream of Src family kinases in this pathway. Fc gammaRI stimulation in human macrophages was associated with rapid and transient tyrosine phosphorylation of the Cbl adaptor protein. Immunoprecipitated Cbl was complexed with several tyrosine phosphorylated proteins, the most prominent of which was a 38-kDa band identified as the CrkL adaptor protein. CrkL associated with tyrosine-phosphorylated Cbl and itself became tyrosine phosphorylated after Fc gammaRI cross-linking. SLP-76, a recently cloned Grb2-associated protein, was strongly tyrosine phosphorylated after Fc gammaRI stimulation and was associated with both Cbl and Grb2. Grb2 and Cbl binding to SLP-76 were inducible after Fc gammaRI stimulation of the macrophages. Nck was inducibly bound to Cbl after Fc gammaRI stimulation, whereas Grb2 was constitutively associated with it. Shc was also inducibly tyrosine phosphorylated and bound to Grb2 after Fc gammaRI stimulation of the macrophages. PP1, a specific inhibitor of Src kinases, inhibited the Fc gammaRI-induced respiratory burst, as well as the tyrosine phosphorylation of Cbl and its inducible association with CrkL. These results suggest a fundamental role for the tyrosine phosphorylation of Cbl, CrkL, SLP-76, and Shc and the association of Cbl with CrkL, SLP-76, and Nck in Fc gammaRI signaling in human macrophages. Experiments performed with PP1, the specific Src kinase inhibitor, demonstrate the first evidence that Cbl and the Cbl-Crkl interaction are downstream targets for myeloid Src kinases required for the activation of myeloid NADPH oxidase activity.


Subject(s)
Adaptor Proteins, Signal Transducing , Adaptor Proteins, Vesicular Transport , Macrophages/metabolism , Proto-Oncogene Proteins/physiology , Receptors, IgG/physiology , Signal Transduction/physiology , Ubiquitin-Protein Ligases , src-Family Kinases/physiology , Bone Marrow Cells , Cells, Cultured , ErbB Receptors/metabolism , ErbB Receptors/physiology , GRB2 Adaptor Protein , Humans , Macrophages/enzymology , Oncogene Proteins/metabolism , Oncogene Proteins/physiology , Phosphoproteins/metabolism , Phosphoproteins/physiology , Phosphorylation , Proteins/metabolism , Proteins/physiology , Proto-Oncogene Proteins c-cbl , Shc Signaling Adaptor Proteins , Src Homology 2 Domain-Containing, Transforming Protein 1 , Tyrosine/metabolism , U937 Cells
9.
Curr Opin Mol Ther ; 1(5): 553-7, 1999 Oct.
Article in English | MEDLINE | ID: mdl-11249661

ABSTRACT

Animal xenograft models of gene therapy have become increasingly popular to study the effects of various transduction strategies on human hematopoietic stem cells (HSC). Xenograft models provide an in vivo setting in which to monitor the duration and effects of vector expression in the progeny of the transduced stem and progenitor cells. Also, the ability of HSC to home to the bone marrow and differentiate into multilineage progeny following ex vivo manipulation can only be tested in a transplantation system. The current review will discuss the murine xenograft models that have been used recently to determine optimized methods for gene transfer into normal human hematopoietic stem cells.


Subject(s)
Gene Transfer Techniques , Hematopoietic Stem Cell Transplantation , Animals , Cell Cycle , Genetic Vectors , Graft Survival , HIV/genetics , Humans , In Vitro Techniques , Mice , Models, Biological , Moloney murine leukemia virus/genetics , Transplantation, Heterologous
10.
Bone Marrow Transplant ; 24(11): 1167-76, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10642804

ABSTRACT

The lack of human B lymphocyte development in beige/nude/XID (bnx) mice is in sharp contrast to the robust development observed in another immune deficient strain, the NOD/SCID mouse. The ability to generate human B lymphocytes in the NOD/SCID, but not bnx mouse has been hypothesized to be caused by differences in the microenvironments or systemic cytokine concentrations. In the current studies we report that the differences in development can be primarily attributed to the source of the progenitors transplanted into the mice. The prior studies in bnx mice used cultured pediatric or adult bone marrow (BM) as the source of the CD34+ cells, whereas the NOD/SCID studies have predominantly used fresh or cultured umbilical cord blood (UCB). We have analyzed BM and UCB for the number of human CD34+/CD38- cells capable of in vitro B lymphocyte development, and have found a lower frequency of B lymphocyte generation in BM. The individual B lymphocyte clones that developed from bone marrow produced 100-fold fewer cells than the UCB-derived clones. In agreement with the in vitro studies, human B lymphocytes developed in bnx mice from both CD34+ and CD34+/CD38- cells isolated from human umbilical cord blood, but not from equivalent numbers of CD34+ and CD34+/CD38- progenitors from bone marrow. Therefore, the lower generative capacity, and frequency of B lymphocyte precursors in human marrow may be responsible for the previous results that showed a lack of B lymphocyte development in bnx mice.


Subject(s)
Antigens, CD , B-Lymphocytes/cytology , Bone Marrow Transplantation , Fetal Blood/cytology , Hematopoietic Stem Cells/cytology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Adolescent , Adult , Animals , Antigens, CD34/analysis , Antigens, Differentiation/analysis , B-Lymphocytes/transplantation , Bone Marrow Cells/cytology , Cell Differentiation , Cell Division , Child , Child, Preschool , Hematopoiesis , Hematopoietic Stem Cell Transplantation , Humans , Lymphocyte Count , Membrane Glycoproteins , Mice , Mice, SCID , NAD+ Nucleosidase/analysis , Stromal Cells/transplantation , Transplantation, Heterologous/methods
11.
Blood ; 92(12): 4612-21, 1998 Dec 15.
Article in English | MEDLINE | ID: mdl-9845527

ABSTRACT

Recent reports have indicated that there is poor engraftment from hematopoietic stem cells (HSC) that have traversed cell cycle ex vivo. However, inducing cells to cycle in culture is critical to the fields of ex vivo stem cell expansion and retroviral-mediated gene therapy. Through the use of a xenograft model, the current data shows that human hematopoietic stem and progenitor cells can traverse M phase ex vivo, integrate retroviral vectors, engraft, and sustain long-term hematopoiesis only if they have had the opportunity to engage their integrin receptors to fibronectin during the culture period. If cultured in suspension under the same conditions, transduction is undetectable and the long-term multilineage regenerative capacity of the primitive cells is severely diminished.


Subject(s)
Fibronectins/metabolism , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/drug effects , Transduction, Genetic , Animals , Cell Adhesion/drug effects , Cell Culture Techniques/methods , Cell Survival/drug effects , Cells, Cultured , Clone Cells/chemistry , Clone Cells/cytology , Colony-Forming Units Assay , Drug Resistance/genetics , Hematopoietic Stem Cells/cytology , Humans , Interleukin-3/genetics , Interleukin-3/pharmacology , Membrane Proteins/pharmacology , Mice , Mice, Nude , Stromal Cells/metabolism , Stromal Cells/transplantation , Tissue Distribution , Transplantation, Heterologous
12.
Int J Mol Med ; 1(1): 257-64, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9852228

ABSTRACT

The potentiality of primitive human hematopoietic cells can be profoundly affected by in vitro culture. Due to the growing number of protocols proposed for stem cell gene therapy and ex vivo expansion, it is crucial to define methods to preserve the generative capacity of human stem cells in culture while promoting self-renewal divisions. Stem cell division, homing, and subsequent lineage development can only be studied definitively by marking of pluripotent cells, followed by tracking and clonal analysis of the progeny in a long-term transplantation system. We have developed a bnx/hu xenograft model, in which transduced human hematopoietic cells can be individually tracked into different lineages over the course of one year post-transplantation. The tracking is accomplished by single cell cloning of individual T lymphoid and myeloid progenitors recovered from the marrow of the mice, and clonal integration analysis by the sensitive technique of single-colony inverse PCR. All cells derived from a stem cell transduced by a retroviral vector will carry the unique restriction fragment length polymorphism (RFLP) created by the random integration event. We have used the bnx/hu xenograft system coupled with single-colony inverse PCR to determine that human stem cells require stromal support, fibronectin support with cytokines, or the presence of Flt3 ligand during a 72-h ex vivo culture to maintain the ability to sustain long-term multilineage hematopoiesis.


Subject(s)
Genetic Vectors , Hematopoiesis/physiology , Hematopoietic Stem Cell Transplantation/methods , Retroviridae , Transplantation, Heterologous , Animals , Cell Lineage , Disease Models, Animal , Humans , Mice , Mice, Nude , T-Lymphocytes
13.
Hum Gene Ther ; 9(17): 2629-40, 1998 Nov 20.
Article in English | MEDLINE | ID: mdl-9853529

ABSTRACT

Retroviral gene transfer of the glucocerebrosidase gene to hematopoietic progenitor and stem cells has shown promising results in animal models and corrected the enzyme deficiency in cells from Gaucher patients in vitro. Therefore, a clinical protocol was initiated to explore the safety and feasibility of retroviral transduction of peripheral blood (PB) or bone marrow (BM) CD34+ cells with the G1Gc vector. This vector uses the viral LTR promoter to express the human glucocerebrosidase cDNA. Three adult patients have been entered with follow-up of 6-15 months. Target cells were G-CSF-mobilized and CD34-enriched PB cells or CD34-enriched steady state BM cells, and were transduced ex vivo for 72 hr. Patient 1 had PB cells transduced in the presence of autologous stromal marrow cells. Patient 2 had PB cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. Patient 3 had BM cells transduced in the presence of autologous stroma, IL-3, IL-6, and SCF. At the end of transduction, the cells were collected and infused immediately without any preparative treatment of the patients. The transduction efficiency of the CD34+ cells at the end of transduction was approximately 1, 10, and 1 for patients 1, 2, and 3, respectively, as estimated by semiquantitative PCR on bulk samples and PCR analysis of individual hematopoietic colonies. Gene marking in vivo was demonstrated in patients 2 and 3. Patient 2 had vector-positive PB granulocytes and mononuclear bone marrow cells at 1 month postinfusion and positive PB mononuclear cells at 2 and 3 months postinfusion. Patient 3 had a positive BM sample at 1 month postinfusion but was negative thereafter. These results indicate that gene-marked cells can engraft and persist for at least 3 months postinfusion, even without myeloablation. However, the level of corrected cells (<0.02%) is too low to result in any clinical benefit, and glucocerebrosidase enzyme activity did not increase in any patient following infusion of transduced cells. Modifications of vector systems and transduction conditions, along with partial myeloablation to allow higher levels of engraftment, may be necessary to achieve beneficial levels of correction in patients with Gaucher disease.


Subject(s)
Bone Marrow Cells/metabolism , Gaucher Disease/therapy , Genetic Therapy , Glucosylceramidase/genetics , Retroviridae/genetics , Transduction, Genetic , Adult , Antigens, CD34/analysis , Base Sequence , Bone Marrow Cells/immunology , DNA Primers , Female , Gaucher Disease/enzymology , Gaucher Disease/genetics , Gene Transfer Techniques , Genetic Vectors , Glucosylceramidase/blood , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Mobilization , Humans , Male , Stromal Cells/cytology
14.
Proc Natl Acad Sci U S A ; 95(22): 13006-11, 1998 Oct 27.
Article in English | MEDLINE | ID: mdl-9789031

ABSTRACT

Successful gene therapy depends on stable transduction of hematopoietic stem cells. Target cells must cycle to allow integration of Moloney-based retroviral vectors, yet hematopoietic stem cells are quiescent. Cells can be held in quiescence by intracellular cyclin-dependent kinase inhibitors. The cyclin-dependent kinase inhibitor p15(INK4B) blocks association of cyclin-dependent kinase (CDK)4/cyclin D and p27(kip-1) blocks activity of CDK2/cyclin A and CDK2/cyclin E, complexes that are mandatory for cell-cycle progression. Antibody neutralization of beta transforming growth factor (TGFbeta) in serum-free medium decreased levels of p15(INK4B) and increased colony formation and retroviral-mediated transduction of primary human CD34(+) cells. Although TGFbeta neutralization increased colony formation from more primitive, noncycling hematopoietic progenitors, no increase in M-phase-dependent, retroviral-mediated transduction was observed. Transduction of the primitive cells was augmented by culture in the presence of antisense oligonucleotides to p27(kip-1) coupled with TGFbeta-neutralizing antibodies. The transduced cells engrafted immune-deficient mice with no alteration in human hematopoietic lineage development. We conclude that neutralization of TGFbeta, plus reduction in levels of the cyclin-dependent kinase inhibitor p27, allows transduction of primitive and quiescent hematopoietic progenitor populations.


Subject(s)
Cell Cycle Proteins , Cell Cycle/physiology , Cyclin-Dependent Kinases/antagonists & inhibitors , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/physiology , Microtubule-Associated Proteins/metabolism , Transforming Growth Factor beta/pharmacology , Tumor Suppressor Proteins , Animals , Antibodies/pharmacology , Antigens, CD/analysis , Antigens, CD34/analysis , Bone Marrow Cells/cytology , Cell Cycle/drug effects , Clone Cells , Colony-Forming Units Assay , Cyclin-Dependent Kinase Inhibitor p27 , Genetic Vectors , Hematopoietic Stem Cells/drug effects , Humans , Immunomagnetic Separation , Mice , Mice, Nude , Mice, SCID , Microtubule-Associated Proteins/antagonists & inhibitors , Moloney murine leukemia virus , Oligonucleotides, Antisense/pharmacology , T-Lymphocytes/cytology , Thionucleotides , Transduction, Genetic , Transforming Growth Factor beta/antagonists & inhibitors , Transforming Growth Factor beta/immunology
15.
Nat Med ; 4(7): 775-80, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9662367

ABSTRACT

Adenosine deaminase-deficient severe combined immunodeficiency was the first disease investigated for gene therapy because of a postulated production or survival advantage for gene-corrected T lymphocytes, which may overcome inefficient gene transfer. Four years after three newborns with this disease were given infusions of transduced autologous umbilical cord blood CD34+ cells, the frequency of gene-containing T lymphocytes has risen to 1-10%, whereas the frequencies of other hematopoietic and lymphoid cells containing the gene remain at 0.01-0.1%. Cessation of polyethylene glycol-conjugated adenosine deaminase enzyme replacement in one subject led to a decline in immune function, despite the persistence of gene-containing T lymphocytes. Thus, despite the long-term engraftment of transduced stem cells and selective accumulation of gene-containing T lymphocytes, improved gene transfer and expression will be needed to attain a therapeutic effect.


Subject(s)
Adenosine Deaminase/immunology , Antigens, CD34/immunology , Hematopoietic Stem Cell Transplantation , T-Lymphocytes/immunology , Transplantation Immunology/immunology , Adenosine Deaminase/deficiency , Adenosine Deaminase/genetics , Adenosine Deaminase/metabolism , Animals , Animals, Newborn , Cell Line , Flow Cytometry , Gene Frequency , Granulocytes/immunology , Humans , Leukocytes, Mononuclear/immunology , Lymphocyte Count , Mice , Mice, SCID , Polyethylene Glycols , T-Lymphocytes/drug effects , Transformation, Genetic , Transplantation, Autologous , Umbilical Cord
16.
Blood ; 91(4): 1243-55, 1998 Feb 15.
Article in English | MEDLINE | ID: mdl-9454754

ABSTRACT

Retroviral-mediated transduction of human hematopoietic stem cells to provide a lifelong supply of corrected progeny remains the most daunting challenge to the success of human gene therapy. The paucity of assays to examine transduction of pluripotent human stem cells hampers progress toward this goal. By using the beige/nude/xid (bnx)/hu immune-deficient mouse xenograft system, we compared the transduction and engraftment of human CD34+ progenitors with that of a more primitive and quiescent subpopulation, the CD34+CD38- cells. Comparable extents of human engraftment and lineage development were obtained from 5 x 10(5) CD34+ cells and 2,000 CD34+CD38- cells. Retroviral marking of long-lived progenitors from the CD34+ populations was readily accomplished, but CD34+CD38- cells capable of reconstituting bnx mice were resistant to transduction. Extending the duration of transduction from 3 to 7 days resulted in low levels of transduction of CD34+CD38- cells. Flt3 ligand was required during the 7-day ex vivo culture to maintain the ability of the cells to sustain long-term engraftment and hematopoiesis in the mice.


Subject(s)
Gene Transfer Techniques , Genetic Vectors , Graft Survival , Hematopoietic Stem Cell Transplantation , Animals , Antigens, CD34 , Genetic Therapy , Humans , Mice , Mice, Nude , Retroviridae/genetics , Transplantation, Heterologous
17.
Exp Hematol ; 25(13): 1357-66, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9406995

ABSTRACT

The ultimate goal of human gene therapy in treating hematopoietic disorders is to insert a functional copy of the affected gene into self-renewing stem cells. The engineered pluripotent cells should then provide all lineages of corrected blood cells for the lifetime of the recipient. It is therefore important to develop methods of tracking and studying the progeny of individual human hematopoietic stem cells. Using the technique of single-colony inverse polymerase chain reaction (PCR), we assessed the clonal diversity of marked colony-forming cells that had developed from transduced human hematopoietic progenitors in a long-term xenograft system. The LN retroviral vector, which carries the neo gene, was used to individually mark human CD34+ progenitors. The marked cells were then transplanted into immune-deficient mice for periods of up to 1 year to assess their survival and retention of clonogenic capacity. Following long-term engraftment, bone marrow cells recovered from each mouse were plated in human-specific colony-forming unit (CFU) assay with and without the drug G418, which selects for cells expressing the neo gene. Three weeks later, well-isolated colonies that had grown in G418 were plucked, and PCR for the neo gene was performed to confirm the presence of the vector. Inverse PCR was then performed on neo+ colonies to analyze the integration site of the LN provirus in human DNA. The clonal diversity of G418-resistant (G418R) human CFU recovered from 18 long-term engrafted beige/nude/xid (bnx) mice was assessed. From one to six human hematopoietic precursors had generated all marked colony-forming progenitors (3-39) recovered from the marrow of each animal. To assess the extent of in vitro self-renewal divisions, marrow samples from 22 sets of experiments, with 2-4 mice transplanted in each set, were studied using the single-colony inverse PCR technique. Proviral integrants at identical sites were found in only two mice transplanted with cells transduced in the same flask. The presence of identical integration sites in human progenitors recovered from two mice demonstrated that a long-lived, marked cell had self-renewed in vitro before transplantation and that both daughter cells had retained the capacity to home to the bnx bone marrow and survive for 10 months. Our in vivo xenograft model and the inverse PCR technique have allowed us to identify, trace, and quantitate the clonogenic progeny of primitive human hematopoietic cells for up to 1 year after retroviral-mediated transduction.


Subject(s)
Clone Cells/metabolism , Genetic Variation , Genetic Vectors , Hematopoietic Stem Cells/cytology , Immunologic Deficiency Syndromes/genetics , Retroviridae/genetics , Transplantation, Heterologous/physiology , Animals , Cell Transplantation/physiology , Genetic Therapy , Humans , Immunologic Deficiency Syndromes/therapy , Kanamycin Kinase/genetics , Mice , Mice, Mutant Strains , Mice, Nude , Proviruses/genetics , Transduction, Genetic
18.
Cytokines Cell Mol Ther ; 3(2): 81-9, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9287247

ABSTRACT

Interleukin 3 (IL-3) supports the survival of multilineage hematopoietic progenitors, and increases the extent of retrovirally mediated gene transfer into colony-forming cells. However, effects from the supraphysiological levels used in ex-vivo expansion and gene-therapy protocols on subsequent differentiation of human progenitors have not been well defined. In the current studies, the extents of retrovirally mediated transduction and lineage development from CD34+ cells cultured ex vivo in the presence or absence of IL-3 were compared. All transductions were performed in the presence of an irradiated stromal support layer, IL-6 and SCF, with and without inclusion of 10 ng/ml IL-3. Following transduction, colony-forming (CFU) assays were done, and the remaining cells were transplanted into cohorts of sibling beige/nude/xid (bnx) mice. Marrow from the mice was harvested 9-10 months post transplantation. The average extent of human CD45+ cell engraftment in the bone marrow and the human hematopoietic lineages recovered from the mice in the +IL-3 and -IL-3 groups did not vary significantly. No deleterious effects on the extent of engraftment, lineage generation, or survival of clonogenic progenitors was observed with inclusion of IL-3 in the transductions performed on stromal support. The percentage of G418-resistant human progenitors recovered from mice was equivalent. The extent of marking by the neo gene in the marrow of the mice was equal in both groups, and inverse PCR revealed that primitive cells transduced in the absence of IL-3 had generated progeny with slightly better clonal diversity than progenitors transduced in the presence of IL-3. These data show that, while transduction of colony-forming progenitors may not always be apparent, primitive human hematopoietic cells can be transduced to significant levels in the absence of IL-3.


Subject(s)
Gene Transfer Techniques , Hematopoietic Stem Cells/drug effects , Interleukin-3/pharmacology , Animals , Antigens, CD34/metabolism , Colony-Forming Units Assay , Genetic Therapy , Genetic Vectors , Graft Survival , Hematopoiesis/drug effects , Hematopoietic Stem Cell Transplantation , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Humans , Mice , Mice, Nude , Retroviridae/genetics , Transduction, Genetic , Transplantation, Heterologous
19.
Blood ; 89(2): 446-56, 1997 Jan 15.
Article in English | MEDLINE | ID: mdl-9002946

ABSTRACT

Stromal support is required during retroviral-mediated transduction of human bone marrow-derived CD34+ cells to maintain the clonogenicity of the primitive progenitors. We hypothesized that the cytokine FLT3 ligand (FL) might be able to replace the maintenance role provided by the stroma. CD34+ progenitors from human bone marrow were transduced by the retroviral vector LN with the cytokines interleukin-3 (IL-3), IL-6, and stem cell factor (SCF) present in all cultures. Transductions were performed with or without stromal support and with or without the inclusion of 100 U/mL FL. No significant increase in gene transfer into colony-forming cells was obtained by the addition of FL to the cultures. Transduction and survival of more primitive human hematopoietic cells was determined by growth in immune-deficient mice for 7 to 8 months. Human myeloid cells, T lymphocytes, and colony-forming progenitors were recovered from the marrow of mice that had received human cells transduced on stroma or in suspension culture with IL-3, IL-6, SCF, and FL, but not with IL-3, IL-6, and SCF alone. LN provirus was detected by polymerase chain reaction in the marrow recovered from 9 of 10 mice transplanted with human CD34+ cells transduced with stromal support, 5 of 11 mice that received human cells transduced in suspension culture with FL, but none of the 10 mice that received human cells transduced in suspension culture without FL We conclude that FLT3 ligand, in conjunction with IL-3, IL-6, and SCF, preserves the generative capacity of primitive human hematopoietic cells during in vitro transductions in suspension culture.


Subject(s)
Hematopoiesis , Hematopoietic Stem Cells/cytology , Membrane Proteins/pharmacology , Animals , Cell Differentiation/drug effects , Cell Division/drug effects , Cells, Cultured , Gene Transfer Techniques , Genetic Vectors , Hematopoietic Stem Cell Transplantation , Humans , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Ligands , Membrane Proteins/genetics , Mice , Mice, Nude , Retroviridae , Stem Cell Factor/pharmacology
20.
Stem Cells ; 15(6): 443-54, 1997.
Article in English | MEDLINE | ID: mdl-9402657

ABSTRACT

Human hematopoiesis can be supported in beige/nude/ XID (bnx) mice by coinjection of human bone marrow stromal cells engineered to secrete human interleukin 3 (HuIL-3). The major limitation is a total absence of human B cell development in the mice, which could be due to supraphysiological levels of HuIL-3 in the circulation. In an effort to obtain human B lymphoid, as well as T lymphoid and myeloid cell development in the mice, CD34+ cells were coinjected with human marrow stromal cells engineered to secrete human IL-2, IL-7, stem cell factor or FLT3 ligand, +/- IL-3. No single factor other than IL-3 supported sustained human hematopoiesis in the mice, although cytokines were expressed for four to six months post-transplantation. Production of both HuIL-3 and IL-7 in the mice supported extrathymic development of human T lymphocytes, but no B cells, myeloid cells, or clonogenic progenitors were detected. Human B cells were not produced from CD34+ cells in the bnx mice under any condition tested. Another limitation to the bnx/Hu system is a lack of maturation of human red blood cells, although BFU-E are maintained. Stromal cells secreting human erythropoietin and IL-3 were cotransplanted into mice with HuCD34+ cells and an increase in hematocrit from 40%-45% to 80%-85% resulted, with production of human and murine red blood cells. Unfortunately, all mice (n = 9) suffered strokes, displayed paralysis and died within three weeks. The bnx/Hu cotransplantation model provides an interesting system in which to study human hematopoietic cell differentiation under the influence of various cytokines.


Subject(s)
Bone Marrow Cells/metabolism , Cytokines/pharmacology , Hematopoiesis , Animals , Antigens, CD34/immunology , B-Lymphocytes/cytology , Bone Marrow Cells/cytology , Cytokines/biosynthesis , Cytokines/genetics , Hematopoietic Stem Cell Transplantation , Humans , Mice , Mice, Nude , Models, Biological , Recombinant Proteins/pharmacology , Stromal Cells/metabolism , Stromal Cells/transplantation , T-Lymphocytes/cytology , T-Lymphocytes/metabolism , Time Factors , Transplantation Chimera , Transplantation, Heterologous
SELECTION OF CITATIONS
SEARCH DETAIL
...